Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE: 300573)

Shenyang Xingqi Pharmaceutical Co.,Ltd. Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	1,649	1,440	1,227	1,024	683.22	538.66
Other Revenue	25.17	27.86	23.2	3.6	5.46	3.78
Revenue	1,674	1,468	1,250	1,028	688.68	542.43
Revenue Growth (YoY)	25.41%	17.42%	21.59%	49.26%	26.96%	25.80%
Cost of Revenue	372.17	340.36	270.08	229.01	187.87	147.18
Gross Profit	1,302	1,127	979.78	798.91	500.81	395.26
Selling, General & Admin	756.96	689.8	595.39	456.54	321.34	292.04
Research & Development	168.29	167.3	145.61	88.45	63.19	53.97
Other Operating Expenses	6.92	7.16	6.66	13.8	3.14	9.53
Operating Expenses	934.26	867.29	748.58	558.6	388.71	357.77
Operating Income	367.46	259.93	231.2	240.31	112.1	37.49
Interest Expense	-3.36	-1.44	-0.94	-5.99	-5.94	-4.46
Interest & Investment Income	7.61	7.91	9.93	3.98	0.22	0.15
Currency Exchange Gain (Loss)	0.16	0.2	-0.09	-0.13	-0.02	0.01
Other Non Operating Income (Expenses)	6.82	-1.15	-19.31	-1.05	-3.74	-0.59
EBT Excluding Unusual Items	378.7	265.45	220.79	237.12	102.62	32.6
Gain (Loss) on Sale of Assets	0.15	-0.04	0.42	5.16	-0.08	0.01
Asset Writedown	-	-	-0	-0	-	-
Other Unusual Items	-6.57	-0.42	12.51	1.26	-	3.2
Pretax Income	372.26	264.99	233.72	243.54	102.54	35.82
Income Tax Expense	50.65	24.96	22.03	34.43	9.08	6.31
Earnings From Continuing Operations	321.6	240.04	211.68	209.11	93.46	29.51
Minority Interest in Earnings	-	-	-	-14.41	-5.48	6.38
Net Income	321.6	240.04	211.68	194.7	87.98	35.89
Net Income to Common	321.6	240.04	211.68	194.7	87.98	35.89
Net Income Growth	79.86%	13.39%	8.72%	121.31%	145.11%	162.79%
Shares Outstanding (Basic)	175	174	172	160	158	156
Shares Outstanding (Diluted)	175	174	172	160	161	156
Shares Change (YoY)	1.93%	1.06%	7.46%	-0.31%	2.88%	-0.77%
EPS (Basic)	1.83	1.38	1.23	1.22	0.56	0.23
EPS (Diluted)	1.83	1.38	1.23	1.21	0.55	0.23
EPS Growth	76.46%	12.21%	1.18%	120.42%	139.94%	164.82%
Free Cash Flow	210.96	55.61	-12.96	211.9	14.01	4.11
Free Cash Flow Per Share	1.20	0.32	-0.08	1.32	0.09	0.03
Dividend Per Share	2.633	2.643	0.765	0.332	0.128	0.064
Dividend Growth	158.01%	245.34%	130.79%	159.87%	100.00%	-50.00%
Gross Margin	77.77%	76.81%	78.39%	77.72%	72.72%	72.87%
Operating Margin	21.95%	17.71%	18.50%	23.38%	16.28%	6.91%
Profit Margin	19.21%	16.36%	16.94%	18.94%	12.77%	6.62%
Free Cash Flow Margin	12.60%	3.79%	-1.04%	20.61%	2.03%	0.76%
EBITDA	452.74	337.77	297.23	297.55	157.61	78.05
EBITDA Margin	27.05%	23.02%	23.78%	28.95%	22.89%	14.39%
D&A For EBITDA	85.28	77.85	66.03	57.24	45.51	40.56
EBIT	367.46	259.93	231.2	240.31	112.1	37.49
EBIT Margin	21.95%	17.71%	18.50%	23.38%	16.28%	6.91%
Effective Tax Rate	13.61%	9.42%	9.43%	14.14%	8.86%	17.61%
Revenue as Reported	1,674	1,468	1,250	1,028	688.68	542.43
Advertising Expenses	-	13.81	13	5.22	6.89	5.14

Source: S&P Capital IQ. Standard template. Financial Sources.